About clonoSEQ

A test that’s as determined as today’s cancer treatments

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available1-3, helping your doctor make more informed decisions about your care. clonoSEQ is FDA-cleared in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is CLIA-validated in other types of blood cancer.

clonoSEQ is a blood or bone marrow test1 that measures your cancer at the deepest level currently available1-3, helping your doctor make more informed decisions about your care. clonoSEQ is FDA-cleared in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is CLIA-validated in other types of blood cancer.

clonoSEQ helps your doctor tailor treatment to your needs

clonoSEQ uses next-generation sequencing technology, an advanced testing method that decodes your cancer’s genetic information, to look for unique cancer DNA sequences that serve as “barcodes.” After your diagnosis, clonoSEQ identifies and counts your cancer’s unique “barcodes.” During treatment and remission, clonoSEQ can tell you and your doctor if and how the number of “barcodes” has changed since your last MRD test.1

clonoSEQ is covered by Medicare and other major insurance providers

“If there was one word to describe receiving my MRD results, I would say, hope.”

— Tiffany, a blood cancer patient who had clonoSEQ testing

clonoSEQ provides the most sensitive measurement of MRD currently available1-3

When it comes to cancer, knowledge is power. By precisely tracking MRD both during and after treatment, you and your doctor can be more informed about your response to therapy—and can plan next steps accordingly.

clonoSEQ can identify residual disease that other tests miss4

Your doctor will likely order other tests—like flow tests or routine blood work—to monitor your cancer. This is a good thing! It means your doctor is trying to gather as much information as possible. To best understand how your cancer may be changing over time, these tests can be paired with a highly sensitive MRD testing tool like clonoSEQ.

Measure, then treat. Treat, then measure.
Repeat throughout your journey.

There can be several stages of treatment in your cancer journey. Your doctor may want to monitor your MRD status at various points to track your progress. Your MRD test results with clonoSEQ may guide the choice of which treatment comes next.

Click through to see when your doctor may test you with clonoSEQ.

(1 of 3)

Initial diagnosis1

Identify the DNA of the cancer cells (Clonality (ID) Test)
This clonoSEQ test provides a baseline. Because this test is done on the largest number of cancer cells, it helps clonoSEQ know which cells to look for in later tests.

(2 of 3)

During treatment

Your doctor may want to monitor your progress while you’re undergoing therapy to see how it’s working. You’ll likely receive other types of tests, scans, or screenings alongside clonoSEQ.

(3 of 3)

After treatment

If you’re in remission and off treatment, or if you received a therapeutic procedure, your doctor will likely want to monitor you for a period of time to detect any relapse as early as possible. This will help you plan for potential later-line treatments.

Talk to your doctor about clonoSEQ

Here are some questions to help you start a conversation with your doctor.

  • Is MRD testing with clonoSEQ right for me?
  • I heard that clonoSEQ is the most sensitive MRD test available. Why does that matter for me?
  • What can MRD testing with clonoSEQ tell me about my cancer?
  • How will you incorporate MRD results from clonoSEQ into my treatment plan?
  • At what points during the treatment process should I have a clonoSEQ MRD test?

Be sure to check in with your doctor regularly. This way, you can ensure you are on track with the MRD goals you’ve set together.

Take a look at a sample clonoSEQ report

Sample clonoSEQ Report

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

  1. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
  2. Short N, et al. Am J Hematol. 2019;94(2):257-265.
  1. Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
  2. Data on file. Adaptive Biotechnologies. 2020.